1-5 of 5
Betty Chang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATE TM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Jennifer R. Brown, MD PhD, Peter Hillmen, MB, ChB, PhD, Susan O'Brien, MD, Jaqueline C. Barrientos, MD, Nishitha Reddy, MBBS, MScl, Steven Coutre, MD, Constantine Tam, MD, Stephen Mulligan, MBBS, MD FRACP, FRCPA, Ulrich Jaeger, MD, Paul M. Barr, MD, Richard R. Furman, MD, Thomas J. Kipps, MD, Florence Cymbalista, MD, Patrick Thornton, MD, Federico Caligaris-Cappio, MD, Julio Delgado, MD, Marco Montillo, MD, Sven DeVos, MD, Carol Moreno, MD, John Pagel, MD PhD, Jan A. Burger, MD PhD, Devon Chung, BS, Jennifer Lin, MA, MS, Linda Gau, MS, Betty Chang, PhD, Jesse McGreivy, MD, Danelle F. James, MD MAS, John C. Byrd, MD
Journal: Blood
Blood (2014) 124 (21): 3331.
https://doi.org/10.1182/blood.V124.21.3331.3331
Published: 2014
Journal Articles

Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL

Clinical Trials & Observations
Sarah E. M. Herman, Rashida Z. Mustafa, Jennifer A. Gyamfi, Stefania Pittaluga, Stella Chang, Betty Chang, Mohammed Farooqui, Adrian Wiestner
Journal: Blood
Blood (2014) 123 (21): 3286–3295.
https://doi.org/10.1182/blood-2014-02-548610
Published: 2014
Includes: Supplemental data
Journal Articles

Targeting Myeloproliferative Diseases with JAK2 Inhibitors.

Vadim Markovtsov, PhD, Diane Yu, Marina Gelman, PhD, Wayne Lang, Vanessa C. Taylor, PhD, Stacey Huynh, Roy Frances, Shuling Fang, John McLaughlin, Sohasekhar Bhamidipati, PhD, Jeffrey Clough, PhD, Rajinder Singh, PhD, Gary Park, PhD, David Sweeney, PhD, Elizabeth Tonkin, PhD, Rena Bahjat, PhD, Betty Chang, PhD, Polly Pine, PhD, Ruby Daniel, PhD, Donald G. Payan, PhD, Sacha Holland, PhD, Yasumichi Hitoshi, PhD
Journal: Blood
Blood (2007) 110 (11): 3550.
https://doi.org/10.1182/blood.V110.11.3550.3550
Published: 2007
Journal Articles

An Orally Bioavailable Inhibitor of FLT3 and Syk Kinases Prevents Tumor Growth in Subcutaneously Implanted Human Tumor Xenografts and Promotes Cell Death of FLT3 Mutant AML Cells.

Polly R. Pine, PhD, Rena Bahjat, PhD, Betty Chang, PhD, Vanessa Taylor, Ph.D, Vadim Markovstov, Ph.D, Yasumichi Hitoshi, MD, PhD, Elliott Grossbard, MD
Journal: Blood
Blood (2005) 106 (11): 243.
https://doi.org/10.1182/blood.V106.11.243.243
Published: 2005
Journal Articles

Ligand-inducible interaction of the DRIP/TRAP coactivator complex with retinoid receptors in retinoic acid–sensitive and –resistant acute promyelocytic leukemia cells

Wenlin Shao, Angelika Rosenauer, Koren Mann, Chao-Pei Betty Chang, Christophe Rachez, Leonard P. Freedman, Wilson H. Miller, Jr
Journal: Blood
Blood (2000) 96 (6): 2233–2239.
https://doi.org/10.1182/blood.V96.6.2233
Published: 2000